Tag results:

type I diabetes

AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes

[AVM Biotechnology, LLC (Business Wire)] AVM Biotechnology, LLC, announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease will allow the company to pursue additional research in the use of AVM0703 as a monotherapy and combination therapy to reverse recent onset and established Type 1 Diabetes.

Increased Expression of Viral Sensor MDA5 in Pancreatic Islets and in Hormone-Negative Endocrine Cells in Recent Onset Type 1 Diabetic Donors

[Frontiers in Immunology] The authors used multiplex immunofluorescence imaging analysis to characterize MDA5 expression and distribution in pancreatic tissues obtained from 22 organ donors.

JDRF Announces Support of Civica to Manufacture and Distribute Low-Cost Insulin

[JDRF, Inc. (BioSpace, Inc.)] JDRF, the leading global type 1 diabetes research and advocacy organization, announces a new collaboration with leading diabetes, advocacy, and healthcare partners to support a newly established insulin-centered project from Civica Inc.

Single-Cell Multi-Omics Analysis of Human Pancreatic Islets Reveals Novel Cellular States in Type 1 Diabetes

[Nature Metabolism] Scientists provided a single-cell atlas of pancreatic islets of 24 type 1 diabetes, autoantibody-positive and nondiabetic organ donors across multiple quantitative modalities including ~80,000 cells using single-cell transcriptomics, ~7,000,000 cells using cytometry by time of flight and ~1,000,000 cells using in situ imaging mass cytometry.

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type...

[CRISPR Therapeutics] CRISPR Therapeutics and ViaCyte, Inc. announced the first patient has been dosed in the Phase I clinical trial of VCTX210 for the treatment of type I diabetes.

The IGFBP3/TMEM219 Pathway Regulates Beta Cell Homeostasis

[Nature Communications] Scientists showed that the death receptor TMEM219 was expressed on pancreatic beta cells and that signaling through its ligand insulin-like growth factor binding protein 3 (IGFBP3) led to beta cell loss and dysfunction.